Mesalamine therapy in Reiter's syndrome

A patient with chronic Reiter's syndrome (RS) refractory to nonsteroidal antiinflammatory therapy was prescribed mesalamine (Pentasa) therapy for a 4-month trial. Nine months after discontinuing therapy, mesalamine was reintroduced. A pre and posttreatment ileocolonoscopy with distal ileum biop...

Full description

Saved in:
Bibliographic Details
Published inJournal of rheumatology Vol. 21; no. 3; p. 570
Main Authors Thomson, G T, McKibbon, C, Inman, R D
Format Journal Article
LanguageEnglish
Published Canada 01.03.1994
Subjects
Adult
Aminosalicylic Acids - therapeutic use
Arthritis, Reactive - complications
Arthritis, Reactive - drug therapy
Colitis - drug therapy
Colitis - etiology
Gastroenteritis - complications
Humans
Ileitis - drug therapy
Ileitis - etiology
Male
Mesalamine
Remission Induction
Online AccessGet more information

Cover

More Information
Summary:A patient with chronic Reiter's syndrome (RS) refractory to nonsteroidal antiinflammatory therapy was prescribed mesalamine (Pentasa) therapy for a 4-month trial. Nine months after discontinuing therapy, mesalamine was reintroduced. A pre and posttreatment ileocolonoscopy with distal ileum biopsy was performed. Our patient responded well to mesalamine therapy as measured by improvement in joint count, morning stiffness, and fatigue. Symptoms returned after cessation of therapy. His RS once again went into remission after reintroduction of mesalamine. The pretreatment biopsy revealed inflammatory lesions usually described in the spondyloarthropathies. These lesions improved with resumption of mesalamine therapy.
ISSN:0315-162X